Analytical and Bioanalytical Methods for the Determination of Dipeptidyl
Peptidase-4 Inhibitors in Various Matrices: A Comprehensive Review

Sakshi      Hadawale; Sanjay      Sharma
doi:10.2174/0115733998288292240409060854
Note! Please note that this article is currently in the "Article in Press" stage and is not the final "Version of record". While it has been accepted, copy-edited, and formatted, however, it is still undergoing proofreading and corrections by the authors. Therefore, the text may still change before the final publication. Although "Articles in Press" may not have all bibliographic details available, the DOI and the year of online publication can still be used to cite them. The article title, DOI, publication year, and author(s) should all be included in the citation format. Once the final "Version of record" becomes available the "Article in Press" will be replaced by that.
Abstract

Background: DPP-4 inhibitors, or gliptins, are new oral antidiabetic drugs for type 2 diabetes. They help to regulate insulin and glucagon. These drugs have the advantage of a lower risk of hypoglycemia compared to some other diabetes medications and are typically prescribed when metformin and sulphonylureas have become less effective.
Objective: This review analyses a range of analytical and bioanalytical methods for DPP-4 inhibitors, that use spectroscopic techniques, chromatographic, and hyphenated techniques for analysis. So far, no review comprising all DPP-4 inhibitors has been presented. The primary objective of this review is to present the analysts with various analytical and bioanalytical methods for the quantification and estimation of DPP-4 inhibitors in different matrices.
Methods: To improve understanding, a review was carried out by creating a database of pre-existing research from digital sources such as ScienceDirect, and PubMed. The methodology is shown in the flowchart of the literature selection process.
Conclusion: The comprehensive assessment of methods for analysing DPP-4 inhibitors can be a valuable resource for researchers and healthcare practitioners. Hitherto, no review encompassing all DPP-4 inhibitors has been presented. Therefore, gaps in the data available on a particular subject, need to be required to collect data on a particular construct. The review suggests that chromatographic techniques were majorly used for analysis wherein solvents like acetonitrile, methanol, and buffer solutions were used as mobile phases that can deteriorate HPLC columns and equipment. So, scientists could investigate new methods for the assessment of DPP-4 inhibitors using more eco-friendly solvents.
[1]
Sapra A, Bhandari P. Diabetes (Nursing).  In: StatPearls. Treasure Island, FL: StatPearls Publishing 2024.

[2]
Sultan J, Agarwal N, Sharma S. Characteristics and biological properties of imeglimin hydrochloride, a novel antidiabetic agent: A systematic review. Curr Diabetes Rev  2024; 20(5): e171023222286.
 [http://dx.doi.org/10.2174/0115733998260331231009104035] [PMID: 37855361]

[3]
Sagandira CR, Khasipo AZ, Sagandira MB, Watts P. An overview of the synthetic routes to essential oral anti-diabetes drugs. Tetrahedron  2021; 96: 132378.
 [http://dx.doi.org/10.1016/j.tet.2021.132378]

[4]
Diabetes.  Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes

[5]
IDF diabetes atlas 2021. 2021. Available from: https://diabetesatlas.org/atlas/tenth-edition/

[6]
Das H, Ghosh S, Ganguly D, Malakar S, Biswas P, Ghosh D. Current scenario of diabetic mellitus with recent drug development approaches: A comprehensive review. Neuroquantology  2023; 21(1): 801-23.
 [http://dx.doi.org/10.48047/nq.2023.21.01.NQ20062]

[7]
Ganeva M. Safety profile of dipeptidyl peptidase-4 inhibitors. Trakia J Sci  2023; 21(1): 54-62.
 [http://dx.doi.org/10.15547/tjs.2023.01.009]

[8]
Shaikh S, Lee EJ, Ahmad K, Ahmad SS, Lim JH, Choi I. A comprehensive review and perspective on natural sources as dipeptidyl peptidase-4 inhibitors for management of diabetes. Pharmaceuticals  2021; 14(6): 591.
 [http://dx.doi.org/10.3390/ph14060591] [PMID: 34203048]

[9]
Mohd NJ. A review of dipeptidyl peptidase-4 (DPP-4) and its potential synthetic derivatives in the management of diabetes mellitus. Journal of Angiotherapy  2024; 8(1): 1-12.
 [http://dx.doi.org/10.25163/angiotherapy.819417]

[10]
Saini K, Khan Y, Sharma S. How effective are gliflozins as DPP-4 inhibitors? a computational study. Theor Found Chem Eng  2023; 57(3): 403-10.
 [http://dx.doi.org/10.1134/S0040579523030168]

[11]
Reghunath SR, Rashid M, Chandran VP, Thunga G, Shivashankar KN, Acharya LD. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review. Diabetes Metab Syndr  2023; 17(7): 102790.
 [http://dx.doi.org/10.1016/j.dsx.2023.102790] [PMID: 37329838]

[12]
Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature. Front Mol Biosci  2023; 10: 1130625.
 [http://dx.doi.org/10.3389/fmolb.2023.1130625] [PMID: 37287751]

[13]
Gallwitz B. Clinical use of DPP-4 inhibitors. Front Endocrinol  2019; 10: 389.
 [http://dx.doi.org/10.3389/fendo.2019.00389] [PMID: 31275246]

[14]
Sitagliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB01261

[15]
Saxagliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB06335

[16]
Linagliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB08882

[17]
Vildagliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB04876

[18]
Alogliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB06203

[19]
Gemigliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB12412

[20]
Omarigliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB11992

[21]
Anagliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB12417

[22]
Teneligliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB11950

[23]
Trelagliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB15323

[24]
Evogliptin: Uses, interactions, mechanism of action.  Available from: https://go.drugbank.com/drugs/DB12625

[25]
Xu S, Tatosian D, Mcintosh I, et al. Absorption, metabolism and excretion of [ 14 C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans. Xenobiotica  2018; 48(6): 584-91.
 [http://dx.doi.org/10.1080/00498254.2017.1346333] [PMID: 28665228]

[26]
Furuta S, Smart C, Hackett A, Benning R, Warrington S. Pharmacokinetics and metabolism of [ 14 C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. Xenobiotica  2013; 43(5): 432-42.
 [http://dx.doi.org/10.3109/00498254.2012.731618] [PMID: 23075005]

[27]
Park JW, Kim KA, Park JY. Development of a liquid chromatography/tandem‐mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma. Biomed Chromatogr  2020; 34(2): e4721.
 [http://dx.doi.org/10.1002/bmc.4721] [PMID: 31656058]

[28]
Mowaka S, Ashoush N, Tadros MM, Ayoub BM. Investigation of pharmacokinetic parameters of trelagliptin in Egyptian volunteers using sensitive LC-MS/MS: A comparative study with a Japanese population. J Anal Methods Chem  2021; 2021: 1-9.
 [http://dx.doi.org/10.1155/2021/9664099] [PMID: 34925935]

[29]
Gu N, Park MK, Kim TE, et al. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther  2014; 8: 1709-21.
 [http://dx.doi.org/10.2147/DDDT.S65678] [PMID: 25336915]

[30]
Ravisankar P, Mounika G, Devadasu C, Devalarao G. A simple validated UV Spectrophotometric method for quantitative analysis of Sitagliptin phosphate in pharmaceutical dosage form. J Chem Pharm Res  2020; 7(3): 254-8.

[31]
Anudeepa J, Manavalan R, Venkatanarayanan R. Development of UV-spectrophotometric method for sitagliptin in bulk and pharmaceutical formulation. IJSTE  2015; 3(5): 1352-4.
 [http://dx.doi.org/10.2348/ijset09151352]

[32]
Sunkara N, Neela Maneesha K, Lavanya B, Arunkumar S. UV spectrophotometric method development and validation of sitagliptin in bulk and pharmaceutical dosage form. IJAPCR  2017; 3(3): 577-80.

[33]
Sushma G, Harsh SD, Annapurna MM. Development and validation of new spectrophototmetric methods for the determination of sitagliptin. Acta Sci Pharm Sci  2020; 4(3): 01-5.
 [http://dx.doi.org/10.31080/ASPS.2020.04.0507]

[34]
Pathade P. Development and validation of stability indicating UV spectrophotometric method for the estimation of sitagliptin phosphate in bulk and tablet dosage form. J Pharm Res  2011; 4(3)

[35]
Tarkase KN, Sarode MB, Gulve SA, Gawade A. Development and validation of UV spectrophotometric method for estimation of sitagliptin phosphate. Pharm Lett  2013; 5(3): 315-8.

[36]
Jalkote RN, Kalshetti MS. UV spectrophotometric method development and validation for determination of sitagliptin in API and in pharmaceutical dosage form. World J Pharm Pharm Sci  2019; 8(5): 916-25.
 [http://dx.doi.org/10.20959/wjpps20195-13681]

[37]
Chavhan V, Kadam A. UV spectrophotometric method development and validation for estimation of sitagliptin phosphate in bulk and tablet dosage form by absorption ratio and area under the curve method. J Biolog Scient Opin  2013; 1(4): 317-22.
 [http://dx.doi.org/10.7897/2321-6328.01407]

[38]
Jeyabalan G, Nyola N. Analytical method development and validation of sitagliptin phosphate monohydrate in pure and tablet dosage form by derivative spectroscopy. J Appl Pharm Sci  2013; 3(1): 95-8.
 [http://dx.doi.org/10.7324/JAPS.2013.30118]

[39]
Monila N, Pratap Pulla R, Shabad H, Swathi V, Rajasekhar J, Ramesh A. New extractive method development of sitagliptin phosphate in API and its unit dosage forms by spectrophotometry. IOSR J Pharm Biol Sci  2012; 1(6): 37-40.
 [http://dx.doi.org/10.9790/3008-0163740]

[40]
Ghodeswar P, Jain A, Jain S. Development of First Order Derivative UV-Spectrophotometric Method for the Estimation of Sitagliptin Phosphate. Res J Pharm Technol  2011; 4(4): 631-3.

[41]
Patil S, Ramesh B, Hareesh AR, Patil K, Validated UV. Spectrophotometric method for estimation of sitagliptin phosphate in tablet dosage form. Res J Pharm Technol  2010; 3(3): 798-800.

[42]
Jain P, Chaudhari A, Desai B, Patel S, Patel S, Shimpi H. Development and validation of first order derivative UV-spectrophotometric method for determination of sitagliptin in bulk and in formulation. IJDDR  2011; 3(4): 194-9.

[43]
Maste MM, Bhat AR, Mohite M, Patil D. Spectrophotometric method for estimation of sitagliptin phosphate in bulk and tablet dosage form. IJPFA  2011; 2(2): 47-50.

[44]
Sekaran BC, Rani PA. Development and validation of spectrophotometric method for the determination of DPP-4 inhibitor, sitagliptin, in its pharmaceutical preparations. Eclét Quím  2010; 35(3): 45-53.

[45]
Tapkir AS, Biradar SM, Chaudhari PD. Development and validation of stability indicating HPTLC assay method for estimation of sitagliptin phosphate. Int J Pharm Sci Res  2017; 8(10): 4454.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.8(10).4454-60]

[46]
Ahmed RM, Hadad GM, El-Gendy AE, Ibrahim A. Development of HPLC method for determination of sitagliptin in human plasma using fluorescence detector by experimental design approach. Anal Chem Lett  2018; 8(6): 813-28.
 [http://dx.doi.org/10.1080/22297928.2018.1545603]

[47]
Dayyih WA, Hamad M. Determination of sitagliptin levels in rats serum by HPLC and its pharmacokinetic investigation in existence of sucralose. Indones J Pharm  2018; 29(3): 117-26.
 [http://dx.doi.org/10.14499/indonesianjpharm29iss3pp117]

[48]
Zaid AN, Zaaror AY, Kaddumi A, et al. Stability of extemporaneously prepared sitagliptin phosphate solution. PLoS One  2022; 17(3): e0262068.
 [http://dx.doi.org/10.1371/journal.pone.0262068] [PMID: 35294449]

[49]
Iqbal Q, Bashir S, Jan SU, Malik MZ, Afzal I, Khalid A. Development of a rapid resolution HPLC method for the quantitative determination of sitagliptin in Human plasma. Pak J Pharm Sci  2018; 31(3): 795-9.
 [PMID: 29716857]

[50]
Fares M, Al-Ani I, Hailat M, Khaleel A, Collier P, Al-Ani A. Evaluation the impact of grapefruit juice on sitagliptin pharmacokinetics in healthy rats. Int J Pharm Res  2021; 13(2): 2145-53.
 [http://dx.doi.org/10.31838/ijpr/2021.13.02.271]

[51]
Giordani ACF, Campanharo S, Wingert RN, Bueno ML, Manoel WJ, Garcia VC. Determination of sitagliptin in the presence of its organic impurities using Box-Behnken experimental design for robustness assessment. Pharmazie  2018; 73(8): 442-6.
 [http://dx.doi.org/10.1691/ph.2018.7201]

[52]
Reddy VRB, Raman N, Kumar SB, Rambabu C. Chiral separation of sitagliptin phosphate enantiomer by HPLC using amylose based chiral stationary phase. J Pharm Res  2013; 7(6): 546-50.
 [http://dx.doi.org/10.1016/j.jopr.2013.06.014]

[53]
Mone MK, Jain P, Kurhade S, Sonune DP, Kaduskar RD. Development and validation of a liquid chromatographic enantiomer separation method for the estimation of (S)-enantiomer in sitagliptin. Int J Pharm Sci Res  2014; 5(6): 2382-6.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.5(6).2382-86]

[54]
Spandana T, Goli VVN, Gurupadayya B. In vitro study and pharmacokinetic evaluation of sitagliptin phosphate enantiomers in rat plasma. Bioanalysis  2023; 15(16): 1033-47.
 [http://dx.doi.org/10.4155/bio-2023-0084] [PMID: 37431826]

[55]
Ravanello A, Delgado SL, Marcolino IPA, Codevilla FC, Adams IHA, Rolim MRC. A simple stability-indicating LC-UV method to assay sitagliptin phosphate in tablets. Curr Anal Chem  2012; 8(4): 569-73.
 [http://dx.doi.org/10.2174/157341112803216771]

[56]
Gumieniczek A, Berecka A, Mroczek T, Wojtanowski K, Dąbrowska K, Stępień K. Determination of chemical stability of sitagliptin by LC-UV, LC-MS and FT-IR methods. J Pharm Biomed Anal  2019; 164: 789-807.
 [http://dx.doi.org/10.1016/j.jpba.2018.11.023] [PMID: 30503802]

[57]
D S, E S, E S, Bakshi V. Development and Validation of RP-HPLC Method for the Estimation of Sitagliptin Phosphate in Tablet Dosage Form. Int J Pharm Sci Res  2017; 2(3): 41-5.
 [http://dx.doi.org/10.21477/ijapsr.v2i3.8099]

[58]
Sultana S, Hossain MS, Islam MS, Rouf ASS. Quantitation of sitagliptin in drug product by validated reversed phase liquid chromatographic technique. Dhaka Univ J Pharm Sci  2018; 17(1): 123-9.
 [http://dx.doi.org/10.3329/dujps.v17i1.37128]

[59]
Maste MM, Parate AN, Bhat AR. Validation and application of a high-performance liquid chromatography method for estimation of sitagliptin phosphate from bulk drug and pharmaceutical formulation. Asian J Res Chem  2011; 4(9): 1466-8.

[60]
Qassas KM, Mardin AM, Ghaza H. A validated HPLC stability indicating method for the determination of sitagliptin in bulk drug substance and tablets. Int J Pharm Sci Rev Res  2015; 32(1): 194-8.

[61]
Dangi NS, Bavaskar SR, Barhate SD. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in bulk and tablet dosage form. World J Pharm Res  2016; 5(9): 773-81.
 [http://dx.doi.org/10.20959/wjpr20169-6878]

[62]
Phanisri M, Lakshmi MJ, Rama D, Reddy B, Padmalatha H. Development and validation of RP-HPLC method for quantitative estimation of sitagliptin phosphate in bulk and pharmaceutical dosage forms. World J Pharm Res  2017; 6(16): 1093-110.
 [http://dx.doi.org/10.20959/wjpr201716-10282]

[63]
Dalawai VM, Sanasi DP, Sharma KH. Development and validation of simple effective HPLC method for the quantitative determination of related substance present in sitagliptin phosphate drug substance. Int J Pharm Sci Res  2016; 7(4): 12.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.7(4).1493-02]

[64]
Punagoti RA, Mourya R. Development and validation of new RP-HPLC method for the quantitative estimation of sitagliptin phosphate in bulk and tablet dosage form. Int J Adv Sci Res  2021; 12(3): 301-5.

[65]
Saleh OA, Azzouny EAAES, Enein AHY, Badawey AM. A validated stability indicating HPLC method for determination of sitagliptin. Eur J Chem  2014; 5(3): 497-502.
 [http://dx.doi.org/10.5155/eurjchem.5.3.497-502.1080]

[66]
Pamu S, Patyar S, Thakkalapally L. Development and validation of a novel RP-HPLC analytical method for sitagliptin determination in human plasma. J Pharm Res Int  2021; 33(42B): 92-101.
 [http://dx.doi.org/10.9734/jpri/2021/v33i42B32430]

[67]
Rayidi L, Yunoos Md. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in bulk and its tablet dosage form. J Adv Pharm Educ Res  2013; 3(4): 475-9.

[68]
El-Bagary RI, Elkady EF, Ayoub BM. Simultaneous determination of sitagliptin and metformin in ternary mixture with sitagliptin acid degradation product. Eur J Chem  2013; 4(4): 360-5.
 [http://dx.doi.org/10.5155/eurjchem.4.4.360-365.843]

[69]
Muhammad A, Muhammad NS, Muhammad MH, Rahman J, Ejaz S, Altaf H. Development and validation of an HPLC method for the quantification of sitagliptin in plasma and tablet dosage form. Lat Am J Pharm  2015; 34(3): 456-61.

[70]
Sonune DP, Mone MK. Isolation, characterization of degradation products of sitagliptin and development of validated stability-indicating HPLC assay method for sitagliptin API and tablets. Int J Pharm Sci Res  2013; 4(9): 3494-503.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.4(9).3494-03]

[71]
Kumar DP, Jhansi TN, Rao GS, Jain KK. Method development and validation for enantiomer in sitagliptin hydrochloride by RPHPLC. J Chem Pharm Res  2017; 9(12): 13-7.

[72]
Ramesh T, Rao NP, Suresh K. Enantiomeric separation of sitagliptin by a validated chiral liquid chromatographic method. Anal Methods  2014; 6(1): 223-8.
 [http://dx.doi.org/10.1039/C3AY41626G]

[73]
Gawande V, Narvekar S, Rathor P, Singh AK, Ajgaonkar A, Bamburdekar S. Simple, rapid RP-HPLC method for estimation of sitagliptin from urine and its application in pharmacokinetics. Int J Bioassays  2013; 2(10): 1322-6.

[74]
Gaddala D, Subudhi SK, Snigdha D. RP-HPLC method development and validation for the determination of sitagliptin in bulk and pharmaceutical dosage form. IJARMPS  2019; 4(10): 19-27.

[75]
Vuyyuru NR, Krishna GV, Ramadevi B, Kumar YR. Evaluation of process impurities and degradants of sitagliptin phosphate by validated stability indicating RP-LC method. Asian J Chem  2017; 29(9): 1941-7.
 [http://dx.doi.org/10.14233/ajchem.2017.20632]

[76]
Tang Y, Li X, Wen N, Sun X, Yu M, Li ZG. RP-HPLC determination of the content and the related substances of sitagliptin phosphate. Yaowu Fenxi Zazhi  2009; 29(8): 1370-2.

[77]
Patil S, Ramesh B, Hareesh A, Patil K, Dhokane A. Development and validation of RP-HPLC method for the estimation of sitagliptin phosphate in tablet dosage form. Asian J Res Chem  2010; 3(3): 653-5.

[78]
Loh GOK, Wong EYL, Tan YTF, et al. Simple and rapid LC-MS/MS method for determination of sitagliptin in human plasma and application to bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci  2020; 1159: 122337.
 [http://dx.doi.org/10.1016/j.jchromb.2020.122337] [PMID: 32905988]

[79]
Rochaeny H, Irawan C, Saputro ID, Rahmatia L, Mawaddah NI. Development and validation of an Ultra performance liquid chromatography-tandem mass spectrometry method with liquid-liquid extraction for the quantification of sitagliptin in human plasma using nebivolol as internal standard. Res J Pharm Tech  2022; 15(1): 89-96.
 [http://dx.doi.org/10.52711/0974-360X.2022.00016]

[80]
Moon SJ, Yu KS, Kim MG. An assessment of pharmacokinetic interaction between lobeglitazone and sitagliptin after multiple oral administrations in healthy men. Clin Ther  2020; 42(6): 1047-57.
 [http://dx.doi.org/10.1016/j.clinthera.2020.04.005] [PMID: 32362346]

[81]
Ismail KM, Rao AL, Rao MB. Estimation of sitagliptin in K2EDTA human plasma using UHPLC-MS/MS method. Int J Pharm Chem Biol Sci  2017; 7(4): 459-67.

[82]
Joshi D, Singh B, Rautela A, Semwal N. Analytical method development and validation of UV-visible spectrophotometric method for the estimation of saxagliptin in gastric medium. Glob J Pharm Pharmaceut Sci  2021; 8(2): 59-65.
 [http://dx.doi.org/10.19080/GJPPS.2021.08.555735]

[83]
Koli SN, Belvotagi AV, Mudke RP, Patil SA. UV spectrophotometric method development and validation for estimation of saxagliptin in API and in pharmaceutical dosage form. Int J Pharm Pharm Res  2019; 14(4): 166-79.

[84]
Prasad V, Gouda N. Determination of saxagliptin monohydrate by derivatization UV-vis spectroscopy. Int J Sci Res  2021; 10(11): 353-5.
 [http://dx.doi.org/10.21275/SR20610163533]

[85]
Deshpande SV, Roy MA, Daswadkar SC. Development and validation of UV spectrophotometric method for estimation of saxagliptin in bulk and pharmaceutical dosage form. Int J Pharm Drug Anal  2016; 4(1): 30-4.

[86]
Madhukar A, Mahajan SR, Siral VR, Rathod RB, Ingole BS. Method development and validation of saxagliptin by using UV spectrophotometric and RP-HPLC techniques in bulk and tablet dosage form. J Pharma Res  2023; 12(2): 15-24.

[87]
Shinde BS, Kalshetti MS, Kokane AP. UV-spectrophotometric method development and validation for estimation of saxagliptin in API and pharmaceutical dosage form. Int J Curr Pharm Res  2020; 12(5): 63-6.
 [http://dx.doi.org/10.22159/ijcpr.2020v12i5.39768]

[88]
Bhavya E, Dhere MD. Development of UV spectrophotometric method for estimation of saxagliptin pharmaceutical dosage forms. J Pharm Negat Results  2022; 13(9): 9362-71.
 [http://dx.doi.org/10.47750/pnr.2022.13.S09.1094]

[89]
Moneeb MS. Spectrophotometric and spectrofluorimetric methods for the determination of saxagliptin and vildagliptin in bulk and pharmaceutical preparations. Bull Fac Pharm Cairo Univ  2013; 51(2): 139-50.
 [http://dx.doi.org/10.1016/j.bfopcu.2013.03.003]

[90]
Gurrala S, Raj S, Cvs S, Anumolu DP, Naraparaju S, Nizampet H. Response surface methodology in spectrophotometric estimation of saxagliptin, derivatization with MBTH and ninhydrin. Turk J Pharm Sci  2022; 19(1): 9-18.
 [http://dx.doi.org/10.4274/tjps.galenos.2021.93195] [PMID: 35227036]

[91]
Srividya S, Swetha E, Veeresham C. Development and validation of a High Performance Thin Layer Chromatographic method for quantitative analysis of saxagliptin. Am J Anal Chem  2015; 6(10): 797-806.
 [http://dx.doi.org/10.4236/ajac.2015.610076]

[92]
Zinjad SS, Gaikwad DD. Analytical method development of saxagliptin HCl by RP-HPLC. J Drug Deliv Ther  2019; 9(4): 274-8.
 [http://dx.doi.org/10.22270/jddt.v9i4.3040]

[93]
Chhabda Pawanjeet J, Balaji M, Srinivasarao V, Apparao KMC. Development and validation of simple stability indicating RP-HPLC method for analysis of saxagliptin and its forced degradation impurities in bulk drug and pharmaceutical dosage form. IJRDPL  2014; 3(3): 993-1003.

[94]
Karkhanis VV, Captain AD. Development and validation of a liquid chromatographic method for estimation of saxagliptin in tablet dosage form. Asian J Res Chem  2013; 6(6): 552-4.

[95]
Scheeren LE, Marcolino AIP, Adams AIH, Rolim CMB. Stability indicating RP-LC-PDA method for the quantitative analysis of saxagliptin in pharmaceutical dosage form. Braz J Pharm Sci  2015; 51(2): 461-6.
 [http://dx.doi.org/10.1590/S1984-82502015000200023]

[96]
Abdel-Ghany MF, Abdel-Aziz O, Ayad MF, Tadros MM. Stability-indicating liquid chromatographic method for determination of saxagliptin and structure elucidation of the major degradation products using LC-MS. J Chromatogr Sci  2015; 53(4): 554-64.
 [http://dx.doi.org/10.1093/chromsci/bmu084] [PMID: 25060753]

[97]
Gao J, Yuan Y, Lu Y, Yao M. Development of a rapid UPLC‐MS/MS method for quantification of saxagliptin in rat plasma and application to pharmacokinetic study. Biomed Chromatogr  2012; 26(12): 1482-7.
 [http://dx.doi.org/10.1002/bmc.2720] [PMID: 22334441]

[98]
Sahloul L, Salami M. Development and validation of a new analytical method for determination of linagliptin in bulk by visible spectrophotometer. Sci Rep  2023; 13(1): 4083.
 [http://dx.doi.org/10.1038/s41598-023-31202-w] [PMID: 36906687]

[99]
Mishra M, Verma G. Analytical method development and validation for determination of linagliptin in bulk and dosage form by UV spectroscopy. J Emerg Technol Innov Res  2018; 5(7): 908-12.

[100]
Gurrala S, Anumolu PD, Menkana S, Gandla N, Toddi K. Spectrophotometric estimation of linagliptin using ion-pair complexation and oxidative coupling reactions – A green approach. Thaiphesatchasan  2020; 44(4): 245-50.

[101]
Joshi D, Singh B, Rautela A, Semwal N. Analytical method development and validation of UV-visible spectrophotometric method for the estimation of linagliptin. Glob J Nanomed  2021; 5(5): 555671.
 [http://dx.doi.org/10.19080/GJN.2021.05.555671]

[102]
Dalal A, Tegeli V, Waghmode R. Development and validation of a simple and rapid UV spectrophotometric method for linagliptin in bulk and marketed dosage form. Der Pharma Chemica  2022; 14(2): 23-6.

[103]
Bhole RP, Wankhede SB, Zambare YB, Wankhede TS. High performance thin layer chromatographic determination of linagliptin in pharmaceutical formulations and in biological samples. Int J Pharmaceut Chem Analy  2017; 4(1): 13-9.
 [http://dx.doi.org/10.18231/2394-2797.2017.0004]

[104]
Hanafy A, Mahgoub H. A validated HPLC method for the determination of linagliptin in rat plasma. Application to a pharmacokinetic study. J Chromatogr Sci  2016; 54(9): 1573-7.
 [http://dx.doi.org/10.1093/chromsci/bmw106] [PMID: 27353348]

[105]
Mourad SS, El-Kimary EI, Hamdy DA, Barary MA. Stability-indicating HPLC-DAD method for the determination of linagliptin in tablet dosage form: Application to degradation kinetics. J Chromatogr Sci  2016; 54(9): 1560-6.
 [http://dx.doi.org/10.1093/chromsci/bmw103] [PMID: 27334290]

[106]
Rajbangshi JC, Alam MM, Hossain MS, Islam MS, Rouf ASS. Development and validation of a RP-HPLC method for quantitative analysis of linagliptin in bulk and dosage forms. Dhaka Univ J Pharm Sci  2018; 17(2): 175-82.
 [http://dx.doi.org/10.3329/dujps.v17i2.39173]

[107]
Ayoub BM, El-Bagary RI, Elkady EF. Liquid chromatographic determination of linagliptin in bulk, in plasma and in its pharmaceutical preparation. Int J Biomed Sci  2012; 8(3): 209-14.
 [http://dx.doi.org/10.59566/IJBS.2012.8209] [PMID: 23675275]

[108]
Al-Sabti B, Harbali J. Trace analysis of potential genotoxic impurity N, N ‐dimethylaniline in linagliptin active pharmaceutical ingredient using HPLC. Separ Sci Plus  2020; 3(7): 306-12.
 [http://dx.doi.org/10.1002/sscp.202000026]

[109]
Al-Sabti B, Harbali J. Quantitative determination of potential genotoxic impurity 3‐aminopyridine in linagliptin active pharmaceutical ingredient using HILIC–UV. Biomed Chromatogr  2020; 34(11): e4930.
 [http://dx.doi.org/10.1002/bmc.4930] [PMID: 32579716]

[110]
Nagabhusana Rao T, Sankar GG, Rani JL. High throughput LC-MS/MS method for the quantitation of linagliptin in human plasma by solid phase extraction using 96 well plate format. Int J Pharm Sci Res  2016; 7(3): 1321-30.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.7]

[111]
Kumari B, Khansili A. Analytical method development and validation of UV-visible spectrophotometric method for the estimation of vildagliptin in gastric medium. Drug Res  2020; 70(9): 417-23.
 [http://dx.doi.org/10.1055/a-1217-0296] [PMID: 32746479]

[112]
Prasad PV, Divya K, Ramana MV, Krishnaveni A, Vinay J, Mahadeswar M. Analytical method development and validation for the estimation of vildagliptin in bulk and its dosage form using UV spectrophotometer. Indo Am J Pharm Res  2017; 7(12): 1069-76.

[113]
Naveed S, Rehman H, Qamar F, Zainab S. Method development and validation of Vildagliptin using UV spectrophotometer. Int J Pharm Sci Res  2014; 5(10): 714-7.

[114]
Swathi CA, Santhi OK, Supriya V, Shakirunnisa SK, Sandhya T, Padmalatha RK. Method development and validation of vildagliptin in tablets and dosage form by UV spectrophotometer. World J Pharm Pharm Sci  2021; 10(8): 1830-42.
 [http://dx.doi.org/10.20959/wjpps20218-19577]

[115]
Ansari A, Chadchankar R, Jadhav V, Patil S. UV spectroscopy method development and validation for determination of vildagliptin in bulk and formulation. World J Pharm Pharm Sci  2022; 11(5): 2154-61.
 [http://dx.doi.org/10.20959/wjpps20225-22104]

[116]
Gaikwad GA, Tambe PP. Development and validation of UV spectroscopic method for estimation of vildagliptin in tablet dosage form. EJBPS  2022; 9(8): 427-32.

[117]
Mane SS, Khan MA. Development of UV-Visible spectrophotometric method for the estimation of vildagliptin in different medium. JPharm Biol Sci  2023; 10(2): 83-7.
 [http://dx.doi.org/10.18231/j.jpbs.2022.016]

[118]
Safila N, Zehra A, Muhammad TA. Using UV spectrophotometric method to determine the linearity of vildagliptin brands. Am J Innov Res Appl Sci  2015; 1(1): 6-9.

[119]
Thomas Barden A, Piccoli BL, Volpato NM, Steppe M. Second-order derivative UV spectrophotometric and RP-HPLC methods for the analysis of vildagliptin and application for dissolution study. Drug Analyt Res  2018; 2(1): 46-53.
 [http://dx.doi.org/10.22456/2527-2616.86511]

[120]
Housheh S, Mohammad H, Alahmad Y. Spectrophotometric method for the determination of vildagliptin in bulk and pharmaceutical dosage forms. Int J Pharm Sci Rev Res  2019; 58(2): 117-20.

[121]
Dayoub LA, Amali F. Development of a new visible spectrophotometric analytical method for determination of vildagliptin in bulk and pharmaceutical dosage forms. Res J Pharm Technol  2020; 13(6): 2807-10.
 [http://dx.doi.org/10.5958/0974-360X.2020.00499.0]

[122]
Patil KR, Deshmukh TA, Patil VR. A stability indicating HPTLC method development and validation for analysis of vildagliptin as bulk drug and from its pharmaceutical dosage form. Int J Pharm Sci Res  2020; 11(5): 2310-6.
 [http://dx.doi.org/10.13040/IJPSR.0975-8232.11]

[123]
Boovizhikannan T, Palanirajan VK. RP-HPLC determination of vildagliptin in pure and in tablet formulation. J Pharm Res  2013; 7(1): 113-6.
 [http://dx.doi.org/10.1016/j.jopr.2013.01.001]

[124]
kumar AS, Sandhya A, Vaibhav J, Jain A, Chavhan A. Development of RP-HPLC method for vildagliptin in pharmaceutical dosage form. Int J Pharm Sci Rev Res  2023; 78(1): 36-40.
 [http://dx.doi.org/10.47583/ijpsrr.2023.v78i01.006]

[125]
Kashid AM, Ghorpade DA, Toranmal PP, Dhawale SC. Development and validation of reversed phase HPLC method for the determination of vildagliptin using an experimental design. J Anal Chem  2015; 70(4): 510-5.
 [http://dx.doi.org/10.1134/S1061934815040061]

[126]
Rao KH, Rao AL, Sekhar KBC. Development and validation of HPLC method for the estimation of vildagliptin in pharmaceutical dosage form. Int J Pharm Chem Biol Sci  2014; 2014(2): 361-6.

[127]
Raosaheb JR, Dabhade MP, Kokate SV, Shinde VS, Shaikh WC. RP-HPLC method development and validation of vildagliptin in bulk and dosage form. World J Pharm Pharm Sci  2017; 6(9): 1161-76.
 [http://dx.doi.org/10.20959/wjpps20179-9980]

[128]
Satpathy PR, Goud VM, Bhagya B, Sharma JVC, Shyamala N. Development and validation of RP-HPLC method for the assay of vildagliptin. World J Pharm Pharm Sci  2014; 3(2): 2303-10.

[129]
Malakar A, Bokshi B, Nasrin D. Development and validation of RP-HPLC method for estimation of Vildagliptin from table dosage form. Int J Pharma Sci  2012; 1(1): 90-8.
 [http://dx.doi.org/10.3329/ijpls.v1i1.12947]

[130]
Sultana R, Bachar SC, Rahman F. Development and validation of stability indicating assay method of vildagliptin in bulk and tablet dosage form by RP-HPLC. Int J Pharm Sci Life Sci  2013; 4(4): 2530-4.

[131]
Chaphekar MM, Hamrapurkar P. Development and validation of RP-HPLC assay method for vildagliptin using Qbd approach and its application to forced degradation studies. Int J Pharm Sci Drug Res  2016; 8(3): 157-65.
 [http://dx.doi.org/10.25004/IJPSDR.2016.080306]

[132]
Savale SK. Development and validation of RP-HPLC method for estimation of vildagliptin. Asian J Biomater Res  2017; 3(5): 6-11.

[133]
Khatun R, Mirazzunnabi M. A validated reversed-phase hplc method for the determination of vildagliptin from tablet dosage form. Int J Pharm Sci Life Sci  2013; 2(3): 90-8.
 [http://dx.doi.org/10.3329/ijpls.v2i3.15455]

[134]
Bagary ERI, Elkady EF, Ayoub BM. Liquid chromatographic methods for the determination of vildagliptin in the presence of its synthetic intermediate and the simultaneous determination of pioglitazone hydrochloride and metformin hydrochloride. Int J Biomed Sci  2011; 7(3): 201-8.

[135]
Al-Qudah E, Arar S, Sweidan K. Forced degradation studies of vildagliptin raw material alone and in the presence of excipients using HPLC-UV analysis. J Excip Food Chem  2020; 11(2): 29-41.

[136]
Barden AT, Salamon B, Schapoval EES, Steppe M. Stability-indicating RP-LC method for the determination of vildagliptin and mass spectrometry detection for a main degradation product. J Chromatogr Sci  2012; 50(5): 426-32.
 [http://dx.doi.org/10.1093/chromsci/bms024] [PMID: 22511486]

[137]
Waghulde M, Naik J. Development and validation of analytical method for vildagliptinencapsulated poly-ε-caprolactone microparticles. Mater Today Proc  2018; 5(1): 958-64.
 [http://dx.doi.org/10.1016/j.matpr.2017.11.171]

[138]
Pharne AB, Santhakumari B, Ghemud AS, Jain HK, Kulkarni MJ. Bioanalytical method development and validation of vildagliptin a novel dipeptidyl peptidase IV inhibitor by RP-HPLC method. Int J Pharm Pharm Sci  2012; 4(3): 119-23.

[139]
Peluri K, Rajasekaran S. Stability-indicating RP-UPLC method for determination of vildagliptin in drug substance and its tablet dosage form. J Pharm Res Int  2021; 33(45A): 139-46.
 [http://dx.doi.org/10.9734/jpri/2021/v33i45A32726]

[140]
Kumar N, Devineni SR, Singh G, Kadirappa A, Dubey SK, Kumar P. Identification, isolation and characterization of potential process-related impurity and its degradation product in vildagliptin. J Pharm Biomed Anal  2016; 119: 114-21.
 [http://dx.doi.org/10.1016/j.jpba.2015.11.044] [PMID: 26678178]

[141]
Giordani FAC, Campanharo S, Wingert RN, et al. UPLC-ESI/Q-TOF MS/MS method for determination of vildagliptin and its organic impurities. J Chromatogr Sci  2020; 58(8): 718-25.
 [http://dx.doi.org/10.1093/chromsci/bmaa040] [PMID: 32705127]

[142]
de Andrade C, de Lock AAG, Pigatto MC, Haas SE, Costa TD, de Araújo BV. Validation of LC‐MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis. Biomed Chromatogr  2014; 28(12): 1722-7.
 [http://dx.doi.org/10.1002/bmc.3212] [PMID: 24771661]

[143]
Tiwari A, Sethi VA, Siddiqui AW, Panigrahy BK, Khuroo AH, Tyagi LK. Bioanalytical method development and validation of vildagliptin in rat plasma using LCMS/MS method. Int J Adv Sci Res  2019; 10(3): 22-9.

[144]
Sakthimanigandan K, Ganesh M, Kanthikiran V, Sivakumar T, Jang H. Liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the determination of Vildagliptin in rat plasma. Acta Chromatogr  2015; 27(2): 295-307.
 [http://dx.doi.org/10.1556/AChrom.27.2015.2.7]

[145]
Uçaktürk E. Development of sensitive and specific analysis of vildagliptin in pharmaceutical formulation by gas chromatography-mass spectrometry. J Anal Methods Chem  2015; 2015: 1-7.
 [http://dx.doi.org/10.1155/2015/707414] [PMID: 26682085]

[146]
Supriya P, Latha MN, Kbv R, Ramana G, Harini U, Akm P. Development and validation of UV spectrophotometric and Reversed phase-high performance liquid chromatography-PDA methods for the estimation of alogliptin benzoate. Asian J Pharm Clin Res  2016; 9(1): 282-7.

[147]
Sunil Kumar AVVNK, Reddy TV, Sekharan CB. Spectrophotometric determination of alogliptin in bulk and tablet dosage form using bromate–bromide mixture as brominating agent. Karbala Int J Mod Sci  2017; 3(1): 8-17.
 [http://dx.doi.org/10.1016/j.kijoms.2016.12.002]

[148]
Sunil Kumar AVVNK, Reddy TV, Sekharan CB. Utility of picric acid and 2,4 dinitrophenol as chromogenic reagents for visible spectrophotometric quantification of alogliptin. Bull Fac Pharm Cairo Univ  2017; 55(1): 177-84.
 [http://dx.doi.org/10.1016/j.bfopcu.2017.02.002]

[149]
Yadav PJ, Kadam VN, Mohite SK. Development and validation of UV spectrophotometric method for alogliptin benzoate in bulk drug and tablet formulation. Int J Curr Pharm Res  2014; 4(4): 1286-90.
 [http://dx.doi.org/10.33786/JCPR.2014.v04i04.004]

[150]
Sharma K, Parle A. Development and validation of HPTLC method for estimation of Alogliptin benzoate in bulk drugs and tablet dosage forms. Int Bullet Drug Res  2015; 5(8): 81-9.

[151]
Patil KR, Deshmukh TA, Patil VR. Stability indicating high performance thin layer chromatographic determination of alogliptin benzoate as bulk drug and in tablet dosage form. Am J Pharmtech Res  2019; 9(3): 332-43.
 [http://dx.doi.org/10.46624/ajptr.2019.v9.i3.028]

[152]
Surati JS, Patel VB. Study of degradation behaviour of alogliptin benzoate by stability indicating high performance thin layer chromatographic method. Asian J Chem  2017; 29(7): 1607-11.
 [http://dx.doi.org/10.14233/ajchem.2017.20614]

[153]
Bodiwala KB, Shah S, Thakor J, Marolia B, Prajapati P. Degradation kinetics study of alogliptin benzoate in alkaline medium by validated stability-indicating HPTLC method. J AOAC Int  2016; 99(6): 1505-12.
 [http://dx.doi.org/10.5740/jaoacint.16-0120] [PMID: 27608919]

[154]
Naseef H, Moqadi R, Qurt M. Development and validation of an HPLC method for determination of antidiabetic drug alogliptin benzoate in bulk and tablets. J Anal Methods Chem  2018; 2018: 1-7.
 [http://dx.doi.org/10.1155/2018/1902510] [PMID: 30345140]

[155]
Bertol CD, Friedrich MT, Carlos G, Froehlich PE. Analytical stability-indicating methods for alogliptin in tablets by LC-CAD and LC-UV. J AOAC Int  2017; 100(2): 400-5.
 [http://dx.doi.org/10.5740/jaoacint.16-0183] [PMID: 28118563]

[156]
Hammad SF, Abdallah IA, Bedair A, Mansour FR. Salting-out induced liquid–liquid microextraction for alogliptin benzoate determination in human plasma by HPLC/UV. BMC Chem  2021; 15(1): 2.
 [http://dx.doi.org/10.1186/s13065-020-00729-8] [PMID: 33451337]

[157]
Wadhankar S, Jaiswal N, Badwaik I, Mange M, Randive T. HPLC method for determination of gliptin as antidiabetic drug in bulk and tablets. TIJER - Int J Res  2023; 10(2): 724-32.

[158]
Rao GS, Mallesh K, Kumar GV, Surekha Ch, Rao BV. A validated chiral HPLC method for the enantiomeric purity of Alogliptin benzoate. Pharma Chem  2014; 6(3): 234-9.

[159]
Zhou Y, Zhou W, Sun L, Zou Q, Wei P, OuYang P. Characterization of process‐related impurities including forced degradation products of alogliptin benzoate and the development of the corresponding reversed‐phase high‐performance liquid chromatography method. J Sep Sci  2014; 37(11): 1248-55.
 [http://dx.doi.org/10.1002/jssc.201301384] [PMID: 24616424]

[160]
Madhukar A, Fathima A, Usha A, Kumar ASC, Kumar PA, Usha K. RP-HPLC method development and validation of alogliptin bulk and tablet dosage form. Indo Am J Pharm Sci  2018; 5(4): 2897-904.
 [http://dx.doi.org/10.5281/zenodo.1228358]

[161]
Gs S. C JGB, T TM. Validated RP-HPLC method for the quatitation of alogliptin in bulk and tablet dosage form. Am J Pharmtech Res  2018; 8(2): 140-8.
 [http://dx.doi.org/10.46624/ajptr.2018.v8.i2.010]

[162]
Vinyas M, Velivela S, Yadav G, Pati NB, Gupta VRM. Analytical method development and validation of alogliptin by RP-HPLC method. Res J Pharm Technol  2016; 9(7): 775-8.
 [http://dx.doi.org/10.5958/0974-360X.2016.00148.7]

[163]
Kant R, Bodla RB, Bhutani R, Kapoor G. Enantioselective box behenken optimized hplc-dad method for the simultaneous estimation of alogliptin enantiomorphs in pharmaceutical formulations and their pharmacokinetic study in rat plasma. Adv Pharm Bull  2019; 9(1): 147-58.
 [http://dx.doi.org/10.15171/apb.2019.018]

[164]
Zhang K, Ma P, Jing W, Zhang X. A developed HPLC method for the determination of Alogliptin Benzoate and its potential impurities in bulk drug and tablets. Asian J Pharm Sci  2015; 10(2): 152-8.
 [http://dx.doi.org/10.1016/j.ajps.2015.01.001]

[165]
Yadav PJ, Jadhav SS, Mohite SK. Development and validation of RP-HPLC method for Alogliptin benzoate in bulk drug and dosage form. Int J Pharm Pharm Res  2014; 1(2): 1-9.

[166]
Dhamireddy S, Subudhi SK, Veeramalla S, Kallepelli S, Cheripelli S, Sadashiv NS. RP-HPLC method development and validation of Alogliptin tablet dosage form. IJARMPS  2019; 4(11)

[167]
Daswadkar SC, Roy MA, Walode SG, Mahendra Kumar CB. Optimization of RP-HPLC method for determination of Alogliptin benzoate in bulk and dosage form. Int J Chem Sci  2016; 14(2): 649-60.

[168]
Bagary ERI, Elkady EF, Ayoub BM. Liquid chromatographic determination of alogliptin in bulk and in its pharmaceutical preparation. Int J Biomed Sci  2012; 8(3): 215-8.

[169]
Ravi Y, Rajkamal BB. A validated LC-MS/MS method for the pharmacokinetic study of alogliptin in healthy rabbits. J Appl Pharm Sci  2019; 9(2): 29-37.
 [http://dx.doi.org/10.7324/JAPS.2019.90204]

[170]
Lu Y, Yang D, Li Z, Hang T, Song M. Isolation and characterization of related substances in alogliptin benzoate by LC-QTOF mass spectrometric techniques. J Pharm Biomed Anal  2016; 128: 253-63.
 [http://dx.doi.org/10.1016/j.jpba.2016.04.032] [PMID: 27281581]

[171]
Al-Sabti B, Harbali J. HPLC–MS analysis of four potential genotoxic impurities in alogliptin pharmaceutical materials. J AOAC Int  2022; 105(2): 362-9.
 [http://dx.doi.org/10.1093/jaoacint/qsab152] [PMID: 34849990]

[172]
Muralikrishna R, Rao AL. UPLC-MS/MS assay for Alogliptin in human plasma and its pharmacokinetic application. Int J Res Pharm Chem  2017; 7(4): 558-69.

[173]
Gorumutchu GP, Ratnakaram NV, Kishore VNV. Visible spectrophotometric determination of gemigliptin using charge transfer complex. Orient J Chem  2019; 35(2): 694-9.
 [http://dx.doi.org/10.13005/ojc/350226]

[174]
Cho YS, Lee SH, Lim HS, Bae KS. Pharmacokinetic equivalence of the high dose strength fixed-dose combination tablet of gemigliptin/metformin Sustained Release (SR) and individual component gemigliptin and metformin XR tablets in healthy subjects. J Korean Med Sci  2018; 33(41): e258.
 [http://dx.doi.org/10.3346/jkms.2018.33.e258] [PMID: 30288156]

[175]
Khan H, Shelke VP. Development and validation of RP-HPLC method for the estimation of gemigliptin. Int J Pharm Pharm Res  2018; 13(2): 224-31.

[176]
Luhar SV, Patel KR, Jani GK, Narkhede SB. Stability study of gemigliptin and simultaneous estimation of gemigliptin and its degradation product by RP-HPLC method. J Pharmaceut Sci Bioscient Res  2016; 6(3): 338-46.

[177]
Luhar SV, Patel HA, Jani GK, Malairajan P. Bioanalytical method development and validation of gemigliptin tartrate sesquihydrate. Eur J Biomed Pharm Sci  2017; 4(4): 488-501.

[178]
Choi HY, Noh YH, Kim YH, Kim MJ, Lee SH, Kim JA. Effects of food on the pharmacokinetics of a gemigliptin/metformin sustained-release 50/1,000 mg (25/500 mg x 2 tablets) fixed-dose combination tablet in healthy male volunteers. Int J Clin Pharmacol Ther  2014; 52(5): 381-91.

[179]
Shin D, Cho YM, Lee S, et al. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects. Clin Drug Investig  2014; 34(6): 383-93.
 [http://dx.doi.org/10.1007/s40261-014-0184-3] [PMID: 24627290]

[180]
Choi HY, Kim YH, Kim MJ, et al. Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs R D  2014; 14(3): 165-76.
 [http://dx.doi.org/10.1007/s40268-014-0054-8] [PMID: 24962635]

[181]
Emanuelli J, Schapoval SSE. Stability-Indicating HPLC method for estimation of omarigliptin in tablets – Oxidative and photolytic kinetics and degradation products formed under oxidative conditions. Microchem J  2020; 157: 105084.
 [http://dx.doi.org/10.1016/j.microc.2020.105084]

[182]
Tantawy MA, Hassan AM, Hegazy MA, Kelani KM. Quality and stability profile assessment of the recent antidiabetic omarigliptin by using different chromatographic methods. J Chromatogr Sci  2021; 59(8): 762-9.
 [http://dx.doi.org/10.1093/chromsci/bmaa136] [PMID: 33434917]

[183]
Mowaka S, Ashoush N, Tadros M, El Zahar N, Ayoub B. Enhanced extraction technique of omarigliptin from human plasma—applied to biological samples from healthy human volunteers. Molecules  2020; 25(18): 4232.
 [http://dx.doi.org/10.3390/molecules25184232] [PMID: 32942678]

[184]
Biftu T, Sinha-Roy R, Chen P, et al. Omarigliptin (MK-3102): A novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem  2014; 57(8): 3205-12.
 [http://dx.doi.org/10.1021/jm401992e] [PMID: 24660890]

[185]
Li MF, Hu XX, Ma AQ. Ultra‐high pressure liquid chromatography–tandem mass spectrometry method for the determination of omarigliptin in rat plasma and its application to a pharmacokinetic study in rats. Biomed Chromatogr  2017; 31(10): e3975.
 [http://dx.doi.org/10.1002/bmc.3975] [PMID: 28317144]

[186]
Patil AS, Shirkhedkar AA. Development and validation of five simple UV-spectrophotometry methods for estimation of anagliptin in bulk and in-house tablets. Pharm Methods  2016; 7(2): 127-31.
 [http://dx.doi.org/10.5530/phm.2016.7.19]

[187]
Patil A, Shirkhedkar A. Application of quality by design in the development of HPTLC method for estimation of anagliptin in bulk and in-house tablets. Eurasian J Anal Chem  2017; 12(5): 443-58.
 [http://dx.doi.org/10.12973/ejac.2017.00181a]

[188]
Pandya CP, Rajput SJ. Stress degradation studies of anagliptin, development of validated stability indicating method, degradation kinetics study, identification and isolation of degradation products. Chromatographia  2018; 81(11): 1533-50.
 [http://dx.doi.org/10.1007/s10337-018-3617-y]

[189]
Gong A, Xu J, Jin D, Wang Y, Zhu X. Determination of anagliptin in serum by mixed-hemimicelle magnetic solid-phase extraction with surfactant-coated iron(II, III) nanocomposites and high-performance liquid chromatography. Anal Lett  2018; 51(15): 2415-28.
 [http://dx.doi.org/10.1080/00032719.2018.1431245]

[190]
Malleswar KD, Rao BV, Shylaja S. A validated chiral HPLC method for the enantiomeric purity of anagliptin. Indo Am J Pharm Res  2019; 9(7): 3096-101.

[191]
Hemke AT, Yadav AS, Kapgate MM, Umekar MJ. Determination of intrinsic stability and development of validated stability indicating RP-HPLC method for anagliptin. J Glob Trends Pharm Sci  2020; 11(3): 8181-90.

[192]
Baira SM, Sigalapalli DK, Bathini NB. R S, Talluri MVNK. LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin. J Pharm Biomed Anal  2018; 159: 92-9.
 [http://dx.doi.org/10.1016/j.jpba.2018.06.036] [PMID: 29980024]

[193]
Furuta S, Tamura M, Hirooka H, Mizuno Y, Miyoshi M, Furuta Y. Pharmacokinetic disposition of anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in rats and dogs. Eur J Drug Metab Pharmacokinet  2013; 38(2): 87-96.
 [http://dx.doi.org/10.1007/s13318-013-0119-z] [PMID: 23436178]

[194]
Yadav N, Goyal A. Method development and validation of Teneligliptin in pharmaceutical dosage form by UV spectrophotometric methods. Int J Pharm Chem Anal  2017; 4(3): 54-8.
 [http://dx.doi.org/10.18231/2394-2797.2017.0014]

[195]
Deore KR, Kalkotwar RS. Development and validation of stability indicating UV spectrophotometric method for the estimation of teneligliptin in bulk and tablet dosage form. Int J Adv Eng Manag  2021; 3(7): 3869-71.
 [http://dx.doi.org/10.35629/5252-030738693871]

[196]
Patra P, Ghosh S, Roy T. kumar RBVV. A novel spectrophotometric method development and validation of Tenagliptin in its Tablet dosages form. J Drug Deliv Ther  2019; 9(5): 95-8.
 [http://dx.doi.org/10.22270/jddt.v9i5.3503]

[197]
Tighare KV, Sawale AV. Development and validation of stress degradation studies for quantification of teneligliptin by UV spectroscopic method. World J Pharm Res  2021; 10(7): 902-18.
 [http://dx.doi.org/10.20959/wjpr20217-20784]

[198]
Comparative evaluation of dissolution profile of drug in its formulation by UV spectrophotometry. Int J Pharm Chem Anal  2020; 7(1): 26-31.
 [http://dx.doi.org/10.18231/j.ijpca.2020.004]

[199]
Kshirsagar SA, Mane SB, Hanchate YS, Katte AS, Kulkarni KV. UV spectrophotometric method development and validation for determination of teneligliptin hydrobromide hydrate in API and in pharmaceutical dosage form. Int J Pharm Res Schol  2018; 7(1): 19-27.
 [http://dx.doi.org/10.31638/IJPRS.V7.I1.00008]

[200]
Chitlange SS, Rawat DG, Chandani S. Estimation of anti-diabetic teneligliptin hydrobromide hydrate by RP-HPLC and derivative spectroscopic method. Indo Am J Pharm Res  2016; 6(7): 6144-53.

[201]
Farkade K, Tawar M. Analytical method validation and quantitative analysis for active pharmaceutical ingredient and marketed formulation of teneligliptin hydrobromide by UV spectroscopy. Asian J Pharm Anal  2021; 11(3): 195-8.
 [http://dx.doi.org/10.52711/2231-5675.2021.00034]

[202]
Maruthi R, Chandan RS, Barath M, et al. Analytical method development and validation of teneligliptin by UV spectroscopy. Res J Pharm Technol  2021; 14(1): 75-8.
 [http://dx.doi.org/10.5958/0974-360X.2021.00014.7]

[203]
Karad MD, Barhate VD. Spectrophotometric determination of an antidiabetic drug teneligliptin bulk and pharmaceutical formulations. World J Pharm Res  2016; 5(5): 1625-32.
 [http://dx.doi.org/10.20959/wjpr20165-6222]

[204]
Ghuge BS, Pendhari SS, Malode PA, Anantwar SP. Development and validation of simple UV spectrophotometric method for the determination of teneligliptin hydrobromide hydrate in API and its bulk dosage form. Int J Pharm Res Schol  2017; 6(2): 44-53.

[205]
Patil PM, Jain PS, Surana SJ, Yeole SD. Development and validation of high-performance thin-layer chromatography method for estimation of teneligliptin in bulk and in pharmaceutical formulation. Acta Chimic Pharmaceut Indica  2017; 7(3): 112.

[206]
Lodha SR, Patel KD, Patel SA, Patel SG, Bodiwala KB, Shah SA. Development and validation of HPTLC method for estimation of teneligliptin hydrobromide hydrate in tablet dosage form. J Pharm Appl Sci  2016; 3(1): 26-33.

[207]
Shah DA, Agarwal K, Mehta FA, Patel VB. Stability indicating HPTLC method for the estimation of anti-diabetic drug teneligliptin. Curr Pharm Anal  2018; 14(6): 547-54.
 [http://dx.doi.org/10.2174/1573412913666170918160514]

[208]
Shinde VC, Aher KB, Bhavar GB, Kakad SJ, Chaudhari SR. Development and validation of UV spectrophotometric method and high-performance thin layer chromatographic (HPTLC) method for estimation of teneligliptin hydrobromide in pharmaceutical preparation. Pharm Lett  2016; 8: 291-301.

[209]
Ashwini BS, Nitin DV, Ashwini SC, Vishnu SC. Analytical method development and validation of teneligliptin hydrobromide in pure form by HPLC. World J Pharm Pharm Sci  2017; 5(10): 37-48.

[210]
Nakamaru Y, Hayashi Y, Ikegawa R, et al. Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica  2014; 44(3): 242-53.
 [http://dx.doi.org/10.3109/00498254.2013.816891] [PMID: 23855261]

[211]
Jadhao MP, Game MD, Dange VH. Implementation of quality by design study on analytical method development and validation of teneligliptin hydrobromide. Int J Chem Pharm Anal  2018; 6(1): 1-11.
 [http://dx.doi.org/10.21276/ijcpa]

[212]
Patel BD, Dharsandiya NJ, Chaudhary A. Development and validation of RP-HPLC method for estimation of teneligliptin and its impurity in tablet. Int J Pharm Sci Rev Res  2021; 69(2): 127-33.
 [http://dx.doi.org/10.47583/ijpsrr.2021.v69i02.019]

[213]
Chandana M, Rao MP, Samrajyam B, Sireesha KSKD. Analytical method development and validation of teneligliptin in pharmaceutical dosage form by RP-HPLC method. IJRDO-J Health Sci Nurs  2016; 1(12): 1-12.

[214]
Tighare KV, Sawale AV. Method development, validation and stress degradation study of teneligliptin by RP-HPLC. American Journal of PharmTech Research  2021; 11(3): 36-50.
 [http://dx.doi.org/10.46624/ajptr.2021.v11.i3.004]

[215]
Dahikar GD, Bobade G. Development and validation of stability indicating RP-HPLC method for teneligliptin hydrobromide hydrate. Am J Pharmtech Res  2021; 11(1): 1-12.
 [http://dx.doi.org/10.46624/ajptr.2021.v11.i1.001]

[216]
P N, Siva Kumar R. Bioanalytical method development and validation of teneligliptin using RP-HPLC in rabbit plasma. World J Pharm Res  2017; 6(10): 589-602.
 [http://dx.doi.org/10.20959/wjpr201710-9225]

[217]
Lokhande DP. Analytical method development and validation of teneligliptin by using RP-HPLC with ICH guidelines. IJTSRD  2019; 3(-3): 259-63.
 [http://dx.doi.org/10.31142/ijtsrd21735]

[218]
Biswas B, Kumar M, Sharma JB, Saini V, Bhatt S. Method development and validation for estimation of teneligliptin in tablet dosage form by RP-HPLC. Res J Pharm Technol  2020; 13(4): 1774-8.
 [http://dx.doi.org/10.5958/0974-360X.2020.00320.0]

[219]
Nagarajan KPRGABPG. Development and validation of fast and sensitive RP-HPLC stability indicating method for quantification of teneligliptin in bulk drug. J Chromatogr Sci  2023; 2023: bmad061.

[220]
Pulate C, Tare H, Dama G. Method development and validation of teneligliptin by RP-HPLC method. Int J Biol Pharm Allied Sci  2021; 10(10): 111-8.
 [http://dx.doi.org/10.31032/IJBPAS/2021/10.10.1010]

[221]
Dandge VD, Malve V, Waghulkar VM, Baitule AW, Jawarkar SG. Development and validation of a bioanalytical method for determination of teneligliptin in human plasma by RP-HPLC. Int J Pharm Tech Res  2022; 2022(2): 48-57.
 [http://dx.doi.org/10.20902/IJPTR.2022.150204]

[222]
Kumar TNVG, Vidyadhara S, Narkhede NA, Silpa YS, Lakshmi MR. Method development, validation, and stability studies of teneligliptin by RP-HPLC and identification of degradation products by UPLC tandem mass spectroscopy. J Anal Sci Technol  2016; 7(1): 27.
 [http://dx.doi.org/10.1186/s40543-016-0107-4]

[223]
Kumari VM, Eswaramma P. Analytical method development and validation of teneligliptin in pharmaceutical dosage form by RP-HPLC. Eur J Biomed Pharm Sci  2017; 4(6): 477-81.

[224]
Ganorkar VA, Jibhkate SR, Radheshyam GK. Development of stability indicating and robust RP-HPLC method for determination of teneligliptin. Asian J Appl Chem Res  2018; 1(4): 1-12.
 [http://dx.doi.org/10.9734/ajacr/2018/v1i49701]

[225]
Pudi R, Mukthinuthalapati MA. Validated isocratic liquid chromatographic method for the quantification of teneligliptin in the presence of internal standard. Int J Green Pharm  2018; 12(3): 670-4.

[226]
Mukthinuthalapati MA, Almas S, Baswani R, Angirekula N. Stability indicating ultrafast liquid chromatographic method for the estimation of Teneligliptin (An Anti-diabetic agent). Asian J Pharm  2018; 12(2): 477-83.

[227]
Maruthi R, Chandan RS, Barath M, et al. Analytical method development and validation of teneligliptin by RP-UFLC. Res J Pharm Technol  2020; 13(9): 4035-40.
 [http://dx.doi.org/10.5958/0974-360X.2020.00713.1]

[228]
Paul D, Allakonda L, Satheeshkumar N. A validated UHPLC-QTOF-MS method for quantification of metformin and teneligliptin in rat plasma: Application to pharmacokinetic interaction study. J Pharm Biomed Anal  2017; 143: 1-8.
 [http://dx.doi.org/10.1016/j.jpba.2017.05.026] [PMID: 28544884]

[229]
Shantikumar S, Satheeshkumar N, Srinivas R. Pharmacokinetic and protein binding profile of peptidomimetic DPP-4 inhibitor – Teneligliptin in rats using liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci  2015; 1002: 194-200.
 [http://dx.doi.org/10.1016/j.jchromb.2015.08.023] [PMID: 26340762]

[230]
Maruthi R, Chandan RS, Tengli AK. Characterization of impurities in teneligliptin hydrobromide hydrate by using LCMS/MS and NMR. Res J Pharm Technol  2020; 13(8): 3569-76.
 [http://dx.doi.org/10.5958/0974-360X.2020.00631.9]

[231]
Halabi A, Maatouk H, Siegler KE, Faisst N, Lufft V, Klause N. Pharmacokinetics of teneligliptin in subjects with renal impairment. Clin Pharmacol Drug Dev  2013; 2(3): 246-54.
 [http://dx.doi.org/10.1002/cpdd.29] [PMID: 27121786]

[232]
Oguma T, Kuriyama C, Nakayama K, et al. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats. J Pharmacol Sci  2015; 127(4): 456-61.
 [http://dx.doi.org/10.1016/j.jphs.2015.03.006] [PMID: 25892328]

[233]
Mowaka S, Ayoub BM, Hassan MA, Zaghary WA. Different spectrophotometric methods for simultaneous determination of trelagliptin and its acid degradation product. J Anal Methods Chem  2018; 2018: 1-7.
 [http://dx.doi.org/10.1155/2018/7370651] [PMID: 29629213]

[234]
Zaghary WA, Mowaka S, Hassan MA, Ayoub BM. Suitability of various chromatographic and spectroscopic techniques for analysis and kinetic degradation study of trelagliptin. Sci Rep  2017; 7(1): 17255.
 [http://dx.doi.org/10.1038/s41598-017-17642-1] [PMID: 29222475]

[235]
Luo Z, Chen X, Wang G, et al. Development of a validated HPLC method for the quantitative determination of trelagliptin succinate and its related substances in pharmaceutical dosage forms. Eur J Pharm Sci  2018; 111: 458-64.
 [http://dx.doi.org/10.1016/j.ejps.2017.10.028] [PMID: 29066384]

[236]
Malleswar KD, Rao BV, Rao KV, Shylaja S. A validated chiral HPLC method for the enantiomeric purity of trelagliptin. Indo Am J Pharm Res  2019; 9(11): 582-7.
 [http://dx.doi.org/10.5281/zenodo.3559498]

[237]
Wang Q, Chen X, Zhang C, et al. Determination of the enantiomeric purity of trelagliptin by pre-column derivatization and liquid chromatography on a chiral stationary phase. Chromatographia  2015; 78(21): 1395-400.
 [http://dx.doi.org/10.1007/s10337-015-2946-3]

[238]
Anerao A, Mundekar V, John S, Pradhan N. Development and validation of related substances method by HPLC for analysis of trelagliptin succinate. World J Pharm Pharm Sci  2016; 5(8): 1844-58.
 [http://dx.doi.org/10.20959/wjpps20168-7509]

[239]
Zhang H, Sun L, Zou L, et al. Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds. J Pharm Biomed Anal  2016; 128: 18-27.
 [http://dx.doi.org/10.1016/j.jpba.2016.04.041] [PMID: 27209451]

[240]
Han Y, Chen L, Liu W, et al. An HPLC–MS/MS method for quantitation of trelagliptin and application in a comparative pharmacokinetic study. Bioanalysis  2019; 11(19): 1755-65.
 [http://dx.doi.org/10.4155/bio-2018-0238] [PMID: 31648536]

[241]
Zhou L, Xi W, Zhang H, Sun L, Yu J, Zou Q. The chiral bioconversion and pharmacokinetic analysis of trelagliptin in beagle dog plasma by LC-MS/MS. J Chromatogr Sci  2020; 58(1): 31-6.
 [http://dx.doi.org/10.1093/chromsci/bmz105] [PMID: 31844877]

[242]
Hu XX, Lan T, Chen CC, et al. A rapid and sensitive UHPLC–MS/MS assay for the determination of trelagliptin in rat plasma and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci  2016; 2016: 1033-4.
 [http://dx.doi.org/10.1016/j.jchromb.2016.08.024]

[243]
Purushottam Agrawal Y, Agrawal MY, Jadhav SB, Shinde RJ. Development and validation of novel UV spectrophotometric method for the determination of evogliptin tartarate in pharmaceutical dosage form. Indian J Pharm Educ Res  2020; 54(4): 1174-9.
 [http://dx.doi.org/10.5530/ijper.54.4.214]

[244]
Patel K, Shah U, Joshi H, Patel CN. Derivative spectrophotometric method development and validation for the estimation of evogliptin tartrate in pharmaceutical dosage form. Indian J Pharm Educ Res  2023; 57(1): 228-33.
 [http://dx.doi.org/10.5530/001954640245]

[245]
Srivastava S, Dhaneshwar S, Kawathekar N. Stability-indicating densitometric analysis of evogliptin tartrate in bulk and tablet dosage form. J AOAC Int  2023; 106(6): 1471-7.
 [http://dx.doi.org/10.1093/jaoacint/qsad091] [PMID: 37531285]

[246]
Ahir HM, Damahe DP, Narkhede SB. Development and validation of stability indicating RP-HPLC method for the estimation of evogliptin tartrate in pharmaceutical dosage form. Int J Pharm Sci Rev Res  2022; 72(2): 1-6.
 [http://dx.doi.org/10.47583/ijpsrr.2022.v72i02.001]

[247]
Dolas J, Jawarka S, Rode RJ, Chinchulkar G, Khan M. Novel method development, validation, and stability indicating assay method for evogliptin tartrate in pharmaceutical dosage form by RP-HPLC. J Emerg Technol Innov Res  2022; 9(2): b327-45.

[248]
Chandakavathe BN, Rajmane AD, Shiddanagoudar OJ, Bet SP. Development and validation of RP-HPLC method for estimation of evogliptin in formulation. Int J Pharm Pharm Res  2023; 26(3): 360-8.

[249]
Patel K, Shah UA, Patel CN. Box–Behnken design-assisted optimization of RP-HPLC method for the estimation of evogliptin tartrate by analytical quality by design. Futur J Pharm Sci  2023; 9(1): 57.
 [http://dx.doi.org/10.1186/s43094-023-00509-w]

[250]
Patel A, Patel R, Yadav P. Development and validation of RP-HPLC method for estimation of evogliptin in pharmaceutical dosage form. IJPRA  2021; 6(2): 2249-7781.
 [http://dx.doi.org/10.35629/7781-0602775781]

[251]
Jeong HU, Kim JH, Lee D, Shim H, Lee H, McPhee DJ. In vitro metabolic pathways of the new anti-diabetic drug evogliptin in human liver preparations. Molecules  2015; 20(12): 21802-15.
 [http://dx.doi.org/10.3390/molecules201219808] [PMID: 26690104]

[252]
Lee DY, Kim JH, Shim HJ, Jeong HU, Lee HS. Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs. J Toxicol Environ Health A  2018; 81(11): 453-64.
 [http://dx.doi.org/10.1080/15287394.2018.1451194] [PMID: 29557727]

[253]
Cho K, Joung SK, La S, et al. Bioanalytical validation for the determination of evogliptin and its metabolites m7/m8 in human plasma by liquid chromatography-tandem mass spectrometry. Drug Metab Pharmacokinet  2017; 32(1): S27.
 [http://dx.doi.org/10.1016/j.dmpk.2016.10.127] [PMID: 28131653]

[254]
Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S. Pharmacokinetic/pharmacodynamic interaction between evogliptin and pioglitazone in healthy male subjects. Drug Des Devel Ther  2020; 14: 4493-502.
 [http://dx.doi.org/10.2147/DDDT.S275336] [PMID: 33122892]

[255]
Yu K-S, Rhee S, Lee SH, Yoon SH, Cho J-Y, Jang I-J. Pharmacokinetics of the evogliptin/metformin extended-release (5/1,000 mg) fixed-dose combination formulation compared to the corresponding loose combination, and food effect in healthy subjects. Drug Des Devel Ther  2016; 10: 1411-8.
 [http://dx.doi.org/10.2147/DDDT.S102459] [PMID: 27110098]

[256]
Oh ES, Choi C, Kim CO, et al. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. J Clin Pharm Ther  2017; 42(6): 689-94.
 [http://dx.doi.org/10.1111/jcpt.12604] [PMID: 28806472]

[257]
Hong T, Jin BH, Kim CO, et al. Pharmacokinetics and safety of evogliptin in hepatically impaired patients. Br J Clin Pharmacol  2021; 87(7): 2757-66.
 [http://dx.doi.org/10.1111/bcp.14680] [PMID: 33245796]

[258]
Claux O, Santerre C, Abert-Vian M, Touboul D, Vallet N, Chemat F. Alternative and sustainable solvents for green analytical chemistry. Curr Opin Green Sustain Chem  2021; 31: 100510.
 [http://dx.doi.org/10.1016/j.cogsc.2021.100510]

[259]
Kaya SI, Cetinkaya A, Ozkan SA. Green analytical chemistry approaches on environmental analysis. Trends Environ Anal Chem  2022; 33: e00157.
 [http://dx.doi.org/10.1016/j.teac.2022.e00157]

[260]
Ullah N, Haseeb A, Tuzen M. Application of recently used green solvents in sample preparation techniques: A comprehensive review of existing trends, challenges, and future opportunities. Crit Rev Anal Chem  2023; 2023: 1-20.
 [http://dx.doi.org/10.1080/10408347.2023.2197495] [PMID: 37067946]

[261]
Gaikwad J, Sharma S, Hatware KV. Review on characteristics and analytical methods of tazarotene: An update. Crit Rev Anal Chem  2020; 50(1): 90-6.
 [http://dx.doi.org/10.1080/10408347.2019.1586519] [PMID: 30942085]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0115733998288292240409060854	Print ISSN 1573-3998
Publisher Name Bentham Science Publisher	Online ISSN 1875-6417
Current Diabetes Reviews

Analytical and Bioanalytical Methods for the Determination of Dipeptidyl Peptidase-4 Inhibitors in Various Matrices: A Comprehensive Review

Abstract Play Pause

Related Journals

Related Books

Abstract
